185 related articles for article (PubMed ID: 30425069)
41. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
42. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
[No Abstract] [Full Text] [Related]
43. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
44. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
Sørrig R
Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
[No Abstract] [Full Text] [Related]
45. Clinical Controversies in the Management of Smoldering Multiple Myeloma.
Lomas OC; Ghobrial IM
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-6. PubMed ID: 32223666
[TBL] [Abstract][Full Text] [Related]
46. Smoldering, asymptomatic stage 1, and indolent myeloma.
Greipp PR
Curr Treat Options Oncol; 2000 Jun; 1(2):119-26. PubMed ID: 12057049
[TBL] [Abstract][Full Text] [Related]
47. Crystal-storing histiocytosis associated with smoldering myeloma.
de Haart SJ; Leguit RJ
Blood; 2021 Jul; 138(4):354. PubMed ID: 34323945
[No Abstract] [Full Text] [Related]
48. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
49. Successful treatment of systemic sclerosis coexisting with smoldering myeloma.
Smoleńska Ż; Gogulska Z; Dorniak K; Zdrojewski Z
Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34698468
[No Abstract] [Full Text] [Related]
50. Thalidomide as initial therapy for early-stage myeloma.
Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
Leukemia; 2003 Apr; 17(4):775-9. PubMed ID: 12682636
[TBL] [Abstract][Full Text] [Related]
51. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
52. Smoldering Multiple Myeloma: To Treat or Not to Treat.
Kapoor P; Rajkumar SV
Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862
[TBL] [Abstract][Full Text] [Related]
53. Dilemmas in treating smoldering multiple myeloma.
Ahn IE; Mailankody S; Korde N; Landgren O
J Clin Oncol; 2015 Jan; 33(1):115-23. PubMed ID: 25422486
[TBL] [Abstract][Full Text] [Related]
54. Quick consults in hematology: In support of active surveillance versus treatment of high-risk smoldering multiple myeloma outside of a clinical trial.
Gertz MA
Am J Hematol; 2024 Mar; 99(3):465-467. PubMed ID: 38115609
[No Abstract] [Full Text] [Related]
55. Eruptive ulcerative follicular spicules heralding progression of smoldering multiple myeloma.
Tomasini C; Michelerio A; Brazzelli V
J Cutan Pathol; 2019 Nov; 46(11):844-851. PubMed ID: 31161673
[TBL] [Abstract][Full Text] [Related]
56. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
[No Abstract] [Full Text] [Related]
57. Smoldering multiple myeloma: when to observe and when to treat?
Mateos MV; San Miguel JF
Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213
[TBL] [Abstract][Full Text] [Related]
58. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
[TBL] [Abstract][Full Text] [Related]
59. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.
Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J
Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370
[No Abstract] [Full Text] [Related]
60. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Jagannath S; Laubach J; Wong E; Stockerl-Goldstein K; Rosenbaum C; Dhodapkar M; Jou YM; Lynch M; Robbins M; Shelat S; Anderson KC; Richardson PG
Br J Haematol; 2018 Aug; 182(4):495-503. PubMed ID: 29808907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]